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Abstract
Human African trypanosomiasis (HAT), or sleeping sickness, is a vector-borne disease that ﬂourishes in impoverished, rural parts of
sub-Saharan Africa. It is caused by infection with the protozoan parasite Trypanosoma brucei and is transmitted by tsetse ﬂies of the
genus Glossina. The majority of cases are caused by T. b. gambiense, which gives rise to the chronic, anthroponotic endemic disease in
Western and Central Africa. Infection with T. b. rhodesiense leads to the acute, zoonotic form of Eastern and Southern Africa. The para-
sites live and multiply extracellularly in the blood and tissue ﬂuids of their human host. They have elaborated a variety of strategies for
invading hosts, to escape the immune system and to take advantage of host growth factors. HAT is a challenging and deadly disease
owing to its complex epidemiology and clinical presentation and, if left untreated, can result in high death rates. As one of the most
neglected tropical diseases, HAT is characterized by the limited availability of safe and cost-effective control tools. No vaccine against
HAT is available, and the toxicity of existing old and cumbersome drugs precludes the adoption of control strategies based on preven-
tive chemotherapy. As a result, the keystones of interventions against sleeping sickness are active and passive case-ﬁnding for early
detection of cases followed by treatment, vector control and animal reservoir management. New methods to diagnose and treat
patients and to control transmission by the tsetse ﬂy are needed to achieve the goal of global elimination of the disease.
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Human African trypanosomiasis (HAT), also known as sleep-
ing sickness, is an endemic parasitic disease exclusively
located in intertropical Africa where it is transmitted by the
tsetse ﬂy, its unique vector. This disabling and fatal disease
belongs to the most neglected tropical diseases and has been
shown to promote rural underdevelopment [1,2]. Its preva-
lence has changed during the past 100 years largely because
of control and intervention programmes. Strategies for con-
trol hinge on early diagnosis and treatment, as well as on
vector control [3]. With new diagnostic methods, safe and
effective medicines and vector control tools, global elimina-
tion of the disease might even be possible.
Epidemiology: Distribution and Trends
The occurrence of HAT is restricted to the distribution of
its vector, the tsetse ﬂy, which is exclusively found in sub-
Saharan Africa between 14N and 20S. The disease has a
focal distribution, although there are areas where suitable
habitats for the tsetse ﬂy are found but HAT is not. Species
and sub-species of tsetse ﬂies are separated into three
groups that show different abilities for transmission in
humans [3]. More than 250 discrete active sleeping sickness
foci are recognized, most of which are in poor and remote
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rural areas where health systems are often weak. However,
the disease has also been reported in peri-urban areas.
Sleeping sickness develops in areas from the size of a village
to an entire district [4]. Although the present number of
cases seems negligible on a worldwide scale, the characteris-
tics and focal distribution of the disease can have a great
socioeconomic effect in the affected areas [5]. Characteris-
tics of transmission of the disease report the distribution of
tsetse ﬂy microhabitats along with the occurrence of con-
tacts between people and vectors during activities such as
farming, ﬁshing or hunting. In that sense, displacement of
populations, war and poverty are factors leading to increased
transmission [5]. In West Africa, recent demographic evolu-
tion and climatic dynamics have had an impact on the patho-
genic system of HAT. Hence, the northern tsetse
distribution limit has shifted towards the south, probably
because of a decrease in rainfall combined with the impact
of human pressure [6]. Sleeping sickness foci have also
shifted from the savannah areas to the forest and mangrove
areas of West Africa [7]. Concurrently, some tsetse species,
such as Glossina palpalis, have adapted to high human densi-
ties and are found in the biggest urban centres of West
Africa [8].
The aetiological agents of HAT are tsetse-transmitted pro-
tozoa of the species Trypanosoma brucei. Two sub-species are
responsible for syndromes of markedly different epidemiol-
ogy and geographical range. Trypanosoma brucei gambiense is
mainly transmitted to humans by tsetse ﬂies of the Glossina
palpalis group and has almost exclusively a human reservoir,
although pigs and some wild animal species have been
reported as being smaller reservoirs. It gives rise to chronic,
anthroponotic endemic disease in Western and Central
Africa. Infection with Trypanosoma brucei rhodesiense is trans-
mitted by tsetse ﬂies of the Glossina morsitans group and
involves humans and a substantial reservoir of ungulate wild-
life (mainly antelopes) and cattle. It leads to the acute, zoo-
notic form of Eastern and Southern Africa and tends to
occur in the form of epidemic outbursts.
In 2010, T. b. gambiense was focally endemic in 24 coun-
tries of Western and Central Africa (mainly Angola, Demo-
cratic Republic of the Congo, Central African Republic,
Chad, Republic of the Congo, Coˆte d’Ivoire, Guinea, south-
ern Sudan and northwest Uganda) and caused > 90% of
reported HAT cases, whereas T. b. rhodesiense disease was
endemic in 13 countries of Eastern and Southern Africa
(mainly Malawi, Tanzania, southeast and central Uganda) and
contributed < 5% [1]. The classic geographic separation of
the two forms of disease is jeopardized by the continued
spread of T. b. rhodesiense in Uganda towards the northwest
[9]. Sporadic cases have been reported linked to infection
with species that were previously considered non-human-
pathogenic trypanosomes, e.g. Trypanosoma evansi [3,10].
In the late nineteenth century, Africa experienced several
sleeping sickness epidemics, the most devastating of which
was an epidemic with 300 000–500 000 deaths between
1896 and 1906 that mainly affected the Congo Basin and the
Busoga focus in Uganda and Kenya. A second major epidemic
occurred between 1920 and the late 1940s, which persuaded
the various colonial administrations to invest in vector con-
trol and mobile teams to undertake active surveillance of the
population; these two strategies are still the pillars of control
[11]. The disease was almost eliminated in the mid-1960s,
followed by resurgence in the late 1990s. This re-emergence
was closely linked to a collapse of surveillance and control
activities in most endemic countries in the post-indepen-
dence period, and was further exacerbated by civil conﬂicts
in the region [6,11]. However, a fall in the number of cases
has been noted in recent years. Between 1999 and 2009,
increased control activities have been associated with a drop
in the number of new reported cases in 2009 to below
10 000 for the ﬁrst time in 50 years, although many cases
certainly remain undiagnosed or unreported because of a
lack of speciﬁcity of clinical presentation or their occurrence
in remote or unstable areas, i.e. in areas without surveillance
[1,4,12]. WHO [13] used a ratio of 1 : 3 to 1 : 4 to calculate
the ﬁgure of 50 000–70 000 new cases in 2004. A new HAT
atlas initiative has led to the creation of a geographic data-
base to store and update HAT epidemiological data allowing
the geolocation of autochthonous cases that have been
detected through active and passive surveillance (Fig. 1) [9].
Parasite and Host Response
Trypanosomes are unicellular organisms that belong to the
family Trypanosomatidae and the genus Trypanosoma. In the
initial phase of infection, trypanosomes are restricted to the
lymph and blood systems. At a later stage they are also seen
in brain parenchyma and cerebrospinal ﬂuid (CSF), but are
generally extracellular. Major modiﬁcations of the immune
system have been observed in HAT. These exacerbated
immune reactions do not lead to protection and are involved
in immunopathology disorders. Trypanosomes are sur-
rounded by a surface coat composed of a variable surface
glycoprotein that protects them from lytic factors in human
plasma and is associated with escape to immune reactions.
When infection occurs, this glycoprotein is recognized by
the host’s immune system, triggering the production of IgM
and IgG antibodies. In HAT, an important feature is a dra-
matic increase in IgM levels, including trypanosome-speciﬁc
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antibodies and non-speciﬁc immunoglobulin production
induced by cytokine activation of B cells. Speciﬁc antibodies
neutralize the corresponding trypanosomes, leading to a
decrease of parasitaemia. However, a subset of these trypan-
osomes change their surface coats to a new variant surface
glycoprotein type that is not affected by the circulating anti-
bodies, leading to renewed proliferation until new antibodies
are produced. This sequence is repeated, and the immune
system is therefore unable to eliminate the parasites [14].
Considering the high degree of antigenic variation of the sur-
face glycoprotein, development of a vaccine is unlikely to be
feasible. Some of these antibodies are also raised against
auto-antigens, corresponding to aberrant non-speciﬁc poly-
clonal activation of B cells producing natural auto-antibodies
and also to antigen-driven antibodies induced by molecular
mimicry [15]. Furthermore, the variant surface glycoprotein
is associated with major cytokine network dysfunctions.
These various elements contribute to collateral tissue dam-
age and immunosuppression. Moreover, trypanosomes have
learnt to use immune mechanisms to their own proﬁt
beyond alternative macrophage activation, including host argi-
nase induction that leads to the production of the essential
parasite growth factor L-ornithine and a depletion of L-argi-
nine, the substrate of nitric oxide (NO) synthase, resulting in
lower levels of cytotoxic NO (Fig. 2) [16,17].
Clinical Features and Morbidity
The hallmark of the disease is that it evolves in two distinct
successive stages. The ﬁrst stage is the haemolymphatic
stage, which is deﬁned by the restriction of trypanosomes to
the blood and the lymph systems. The second stage is the
meningo-encephalitic stage, which is characterized by the
active invasion of the central nervous system. If left
untreated, sleeping sickness caused by either of the two par-
asites leads to coma and death. In addition, T. b. gambiense
infection is characterized by a chronic progressive course
with an average duration of around 3 years that can be mis-
taken for a chronic haemopathy condition. In contrast,
FIG. 1. Distribution of human African trypanosomiasis mapped in the Atlas of human African trypanosomiasis: progress status. For each country,
data processing is considered complete when all available data sources for the study period (2000–2009) have been analyzed and included in the
human African trypanosomiasis database. Credit WHO/OMS, reproduced from Simarro et al. [9] with permission.
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T. b. rhodesiense disease presents usually presents as an acute
febrile septico-pyaemia-like illness with poor demarkation
between stages and leading to death within months [18].
After the tsetse bite, a chancre is rarely seen with
T. b. gambiense, (Fig. 3) but occurs and can be numerous in 20%
of patients infected with T. b. rhodesiense. It represents the ini-
tial lesion at the bite site, and is characterized by local ery-
thema, oedema, heat, tenderness and a lack of any suppuration.
The leading signs and symptoms of the ﬁrst stage generally
reported in T. b. gambiense infection, are chronic and
intermittent fever, headache, severe pruritus with scratching,
skin lesions, mobile or rubbery lymphadenopathies, oedema
of the face and extremities and, to a lesser extent, spleno-
megaly or hepatomegaly. Palpation of the sub-clavicular and
cervical regions (Winterbottom sign) is part of the ﬁeld diag-
nostic procedure. Skin eruptions or trypanides are occasion-
ally observed. Cardiovascular alterations are less prominent
in the T. b. gambiense infection and the early occurrence of
myocarditis is considered a pejorative prognostic event [19].
Minor neurological and endocrine disorders reveal the early
central nervous system involvement. Deep hyperaesthesia is
often reported (Kerandel’s sign).
The clinical signs of second-stage HAT are neuro-psychiat-
ric and endocrinal disorders. Sleep disorder accounts for
dysregulation of the circadian rhythm of the sleep–wake
FIG. 2. Human immune response to Trypanosoma infection. Parasite-derived antigens modulate both innate and speciﬁc immune cell activation
and the generation of effector or deleterious responses. (a) High T helper type 1 (Th1) -like response leads in the generation by macrophages
of nitric oxide (NO) and tumour necrosis factor-a (TNF-a), which are well characterized trypanocidal factors. Simultaneous down-regulation of
the Th2 pathway is required to prevent activation of arginase enzyme activity, and providing enough intracellular L-arginine levels for inducible
NO synthase (NOS-II) activity. Low Th2 response also induces B-cell-derived trypanocidal IgM. In contrast, a dominant Th2 response favours
the development of B-cell-derived IgG1, observed during chronic infection (b). Increased arginase activity leads to increased L-ornithine levels,
used by parasites as survival factor. Th2 lymphocytes and, at lower levels, regulatory T cells, inhibit NO generation and increase arginase activity.
L-ornithine is then used by parasites to generate trypanothione/polyamines, required for optimal parasite growth and their protection against
NO. Exacerbation of both Th2 and Th1, together with parasite resistance to NO lead to the generation of deleterious amounts of inﬂammatory
mediators, leading to cachexia and death (c). CTL, cytotoxic T lymphocyte, IFN, interferon; IL-12, interleukin-12; M/, macrophage; NK, natural
killer cell.
FIG. 3. Trypanosomal chancre on the dorsal side of the right ankle
in a 53-year-old French expatriate with Trypanosoma brucei gambiense
infection.
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cycle and a fragmentation of the sleeping pattern rather than
the frequently reported inversion of sleep [20]. The neuro-
logical symptoms include confusion, tremor, fasciculations,
general motor weakness, hemiparesis, akinesia or dyskinesia,
sensory disturbances with diffuse hyperpathia, abnormal
movements and speech disorders. Abnormal archaic reﬂexes
can also arise (palm-mental reﬂex, sucking reﬂex). Psychiatric
symptoms can dominate the clinical picture and may consti-
tute the ﬁrst manifestation of the disease. [21]. Endocrine
disorders of the thyroid and adrenocortical function can take
the form of hypofunction or hyperfunction. A great diversity
of clinical pictures can be seen in patients infected with
T. b. gambiense, suggesting the presence of distinct genetic
groups of trypanosomes [22–24].
At the terminal phase of the disease, central nervous sys-
tem demyelination and atrophy are accompanied by distur-
bances in consciousness with progressive dementia. The
patient dies in a state of cachexia and opportunistic infections.
Mainly during the late stage, stigmatization of patients is com-
mon. Neurological and psychiatric sequelae are frequent.
Diagnosis
Trypanosoma brucei gambiense human African
trypanosomiasis
Diagnosis of T. b. gambiense HAT relies on a three-step path-
way: (i) screening; (ii) parasitological conﬁrmation; and (iii)
staging [25,26]. The Card Agglutination Test for Trypanoso-
miasis (CATT) is a rapid serological screening test used in
the vast majority of HAT control programmes [27]. The
CATT sensitivity on undiluted whole blood is high (87–98%),
which leads to a high negative predictive value of a negative
test result, as the prevalence of HAT in the tested popula-
tion usually lies below 5%. This low pre-test probability also
explains why all individuals with a positive CATT sensitivity
on undiluted whole blood or positive CATT with undiluted
or mildly diluted (CATT 1 : 4) serum) require parasitological
conﬁrmation, despite a reported 95% speciﬁcity. The treat-
ment of serologically suspect patients with a high CATT
titres (‡ 1 : 16) is only acceptable in areas of high disease
prevalence (> 1%), especially when the most sensitive blood
concentration techniques (see below) are not available
[28,29]. Accurate serological tests also exist in immuno-
ﬂuorescence or ELISA formats, but they are mainly in use
in non-endemic countries.
Parasitological conﬁrmation relies on the microscopic
search for trypanosomes in the inoculation chancre smear or
cervical lymph node ﬂuid (sampled by puncture), or in the
blood. As circulating parasites are few, it is necessary to
use blood concentration techniques. Examination of wet
and thick blood smears notoriously lacks sensitivity. The
microhaematocrit centrifugation technique, or capillary tube
centrifugation technique, remains widely used [30]. The mi-
crohaematocrit centrifugation technique sensitivity increases
with the number of capillary tubes examined (six to eight
tubes should be used) but does not exceed 60%. Microscopi-
cal reading of microhaematocrit centrifugation technique can
be made difﬁcult by the concomitant presence of microﬁlaria.
The quantitative buffy coat is more sensitive, allows for eas-
ier discrimination between trypanosomes and white blood
cells, and concomitantly detects malaria parasites [31].
Whereas quantitative buffy coat remains in use in some labo-
ratories, it is not used in the ﬁeld because of its relative
sophistication and irregular availability. The miniature-anion-
exchange centrifugation technique, which consists of separat-
ing the trypanosomes from venous blood and concentrating
them in a collecting tube by centrifugation, is currently the
most sensitive technique for trypanosome detection [32].
Production of this test, which has been hectic during the last
decades, is currently assured by the Institut National de
Recherche Biome´dicale in Kinshasa, Democratic Republic of
the Congo, in collaboration with the Institute of Tropical
Medicine, Antwerp, Belgium [33]. Despite its relatively high
cost (2–3 €/test), the addition of miniature-anion-exchange
centrifugation technique in diagnostic algorithms has been
shown to be cost-effective [34]. Detection of parasite nucleic
acids by PCR may be a more sensitive approach, but further
standardization and diagnostic validation are needed.
Staging by CSF examination after lumbar puncture is man-
datory in all patients with conﬁrmed HAT because treatment
substantially differs between the ﬁrst and second stages. Sec-
ond-stage HAT is deﬁned by the presence of trypanosomes
and/or > 5 white blood cells/lL in the CSF. Some contro-
versy exists about the group of patients with 6–10 cells/lL
regarding the presence of neuroinﬂammation and the equivo-
cal outcomes produced by the use of the ﬁrst-stage disease
drug pentamidine. High IgM concentration in CSF is also a
reliable marker of neurological involvement [35].
Overall, diagnostic tools and algorithms are complex for
use in the context of rural sub-Saharan Africa (Fig. 4), and
currently preclude the re-integration of HAT activities within
public health services outside reference centres. It is there-
fore urgent to develop more practical and accurate diagnos-
tic tests.
Trypanosoma brucei rhodesiense human African
trypanosomiasis
The diagnosis of T. b. rhodesiense HAT follows the same gen-
eral principles (screening, diagnostic conﬁrmation and stag-
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ing) but differs from that for T. b. gambiense is several ways:
(i) in the absence of serological screening test for T. b. rho-
desiense, screening is based on the recognition of non-speciﬁc
clinical features (e.g. fever) and history of exposure (e.g.
tsetse ﬂy bite during a safari in East Africa); (ii) parasitologi-
cal conﬁrmation is easier because of the high density of
blood circulating trypanosomes; and (iii) biological indices,
such as coagulation tests, haemoglobin and platelet counts,
are more frequently and deeply altered.
Treatment
Treatment of HAT, which has been recently reviewed by
Burri [36], includes speciﬁc anti-trypanosomal drugs, on
which we will focus, and concomitant conditions such as bac-
terial infections (e.g. pneumonia), malaria, severe anaemia,
dehydration and malnutrition (Table 1). All anti-trypanosomal
drugs are currently donated to WHO by Bayer Leverkusen,
Germany and sanoﬁ-aventis Paris, France. Drugs can be
ordered from WHO (contact: simarrop@who.int).
Trypanosoma brucei gambiense human African
trypanosomiasis
Treatment for ﬁrst-stage patients has relied on pentamidine
for several decades. Pentamidine is administered intramuscu-
larly or as an intravenous slow infusion for 7 days. The most
frequent adverse effects are pain at the injection site (rarely
complicated by aseptic or septic abscess), hypoglycaemia and
hypotension. Patients are given sweet food or drinks before
–
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FIG. 4. Trypanosoma brucei gambiense human African trypanosomiasis diagnostic algorithm used by Me´decins sans Frontie`res in north-eastern
Democratic Republic of the Congo, 2011.
TABLE 1. Anti-trypanosomal treatment for ﬁrst- and second-stage human African trypanosomiasis
Disease and stage First-line treatment Dosing Other treatment(s)
Trypanosoma brucei gambiense HAT
First-stage Pentamidine isethionate 4 mg/kg/day IM or IV (diluted in saline
and given in 2-h infusions) x 7 days
Second-stage NECT: Eﬂornithine +
Nifurtimox
Eﬂornithine: 400 mg/kg/day IV in 2 (1-h)
infusions x 7 days
Nifurtimox: 15 mg/kg/day PO in
3 doses x 10 days
Eﬂornithine: 400 mg/kg/day IV in 4 infusions x 14 days
Second line (e.g. treatment of relapse): Melarsoprol
2.2 mg/kg/day IV x 10 days
Trypanosoma brucei rhodesiense HAT
First-stage Suramin Test dose of 4–5 mg/kg IV (day 1),
then 20 mg/kg IV weekly x 5 weeks
(maximal dose/injection: 1 g)
Second-stage Melarsoprol 2.2 mg/kg/day IV x 10 days Three series of 3.6 mg/kg/day IV x 3 days spaced by
intervals of 7 days
HAT, human African trypanosomiasis; IM, intramuscular; IV, intravenous; NECT, Nifurtimox–eﬂornithine combination therapy; PO, per os.
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and are advised to lie down for at least 1 h after injection.
Severe complications, such as anaphylaxis and clinical pancre-
atitis, very rarely occur.
Melarsoprol, an arsenic-based derivative, was the only
available treatment for second-stage T. b. gambiense HAT for
more than 50 years. It is a poorly tolerated drug with a
wide-range of adverse effects such as an encephalopathic
syndrome (5–10% frequency with around 50% case-fatality
rate), peripheral neuropathy, hepatic toxicity, skin rash, acute
phlebitis and vein sclerosis. Moreover, high melarsoprol fail-
ure rates have been reported from several endemic coun-
tries. Twenty years after the ﬁrst demonstration of efﬁcacy,
eﬂornithine (a-diﬂuoromethylorntihine or DFMO) has ﬁnally
become available for ﬁeld use since 2000, and was conﬁrmed
to be safer than melarsoprol [37,38]. Eﬂornithine has
gradually replaced melarsoprol as the ﬁrst-line treatment but
universal use has been constrained by the huge requirements
in logistics and nursing care (56 intravenous infusions of
> 30 min over 14 days). The provision of kits by WHO
including all the necessary ancillary materials mitigated some
of the difﬁculties. Efforts to shorten and simplify eﬂornithine-
based therapy have recently been successful, with the com-
pletion of a multicentre clinical trial that demonstrated that a
nifurtimox–eﬂornithine combination therapy (NECT) was
not inferior compared with the standard eﬂornithine treat-
ment [39]. NECT was included in the WHO’s Essential Med-
icines List in May 2009 and a phase IIIb trial (NECT-FIELD)
conducted by the Drugs for Neglected Diseases initiative
(DNDi) with over 600 patients is underway in the Demo-
cratic Republic of the Congo. Me´decins sans Frontie`res has
used NECT as ﬁrst-line treatment in several endemic
countries since January 2010. Out of 341 patients with sec-
ond-stage disease treated in northeastern Democratic
Republic of the Congo by Me´decins sans Frontie`res in 2010,
only one patient died (0.3%) during hospitalization (Chappuis
F, unpublished data).
Trypanosoma brucei rhodesiense human African
trypanosomiasis
Suramin is used for ﬁrst-stage T. b. rhodesiense disease with a
complex dose regimen that last up to 30 days. Nephrotoxi-
city, peripheral neuropathy and bone marrow toxicity are
known adverse effects but are usually mild and reversible.
Rare acute hypersensitivity reactions can occur, explaining
why a low test dose is generally applied before treatment.
Unfortunately, T. b. rhodesiense is innately resistant to eﬂ-
ornithine. Therefore, melarsoprol remains the only effective
treatment for patients with second-stage disease despite its
disastrous safety proﬁle. The abridged treatment schedule of
10 daily injections, initially developed for T. b. gambiense
HAT (IMPAMEL I and II), has recently showed similar safety
and efﬁcacy proﬁles as a prolonged discontinuous regimen
(IMPAMEL III study) [40,41].
Post-treatment follow-up
Follow-up should be proposed for all HAT patients after
treatment, e.g. 6-monthly for 2 years. As adherence to fol-
low-up in endemic areas is usually low, shortening the fol-
low-up period would be desirable. A recent study showed
that most patients can be accurately classiﬁed 6 months
post-treatment as cured (no trypanosomes and £ 5 white
blood cells/lL in CSF) or relapsed (trypanosomes or
> 50 white blood cells/lL in CSF) with the remaining
patients classiﬁed at 12 months using a 20 white blood cells/
lL threshold [42].
Human African Trypanosomiasis Outside
Africa
Imported HAT caused by T. b. gambiense has occasionally
been reported in short-term travellers [35,43], but is more
often encountered in migrants and expatriates residing in
rural or coastal foci [44]. Because of its long incubation per-
iod and indolent course, it may remain unrecognized for
years [45]. Moreover, for a long time it may be misdiagnosed
as a chronic haematological condition. Such undue delay may
lead to diagnosis of the disease at an advanced stage
(Malvy D, unpublished data). In addition, infected migrants to
western countries from endemic foci may be misdiagnosed
as psychiatric patients when there is an unrecognized or
unrevealed history of past exposure [21]. By contrast, HAT
caused by T. b. rhodesiense is more likely to be seen in tour-
ists returning from East African game parks, mainly in Tanza-
nia or Uganda [46–50]. Some emerging tourist destinations
(Botswana, Rwanda, Kenya, Zambia and Malawi) are known
foci and may pose a risk for travellers [51,52]. Of note, the
manifestations of T. b. gambiense and T. b. rhodesiense HAT in
travellers appear more similar than in patients from endemic
countries, with prominence of acute febrile disease with
trypanosomal chancres (Fig. 3) and rash, and severe haema-
tological or electrolyte disturbances [43,45,53]. The only rel-
evant preventive measure for sleeping sickness in travellers
is the avoidance of tsetse ﬂy bites. Tsetse ﬂies are attracted
to dark colours, particularly blue and black, and to the
motion of vehicles. Tsetse ﬂies are capable of biting through
loose weave fabrics and are less affected by many insect
repellents. In travellers, personal preventive measures may
comprise travelling in cars with screened/closed windows,
use of insect repellent containing at least 30% N,N-diethyl-3-
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methylbenzamide (or DEET), and the use of insecticide-trea-
ted thick-weave clothing that is khaki or olive in colour [54].
Finally, in individuals bitten by a tsetse ﬂy, a close monitoring
of the bite site and body temperature for 3 weeks is war-
ranted. Transmission following accidental self-inoculation in a
laboratory worker has been exceptionally reported [55].
Towards the Goal of Elimination
Even though some areas at risk are not covered by control
and surveillance programmes, most foci of sleeping sickness
are historical and well known [56]. Theoretical conditions
for transmission break down seem to be obvious with regard
to the constraints related to the biological cycle of HAT, at
least for T. b. gambiense infection in which animals are not a
substantial reservoir. Herein, transmission through the vec-
tor is complex and slow, with < 0.1% of ﬂies carrying mature
parasites, and the prevalence of infected individuals is usually
low. Infected persons can initially remain asymptomatic for
long periods, acting as a silent reservoir. Hence, the most
important control measure for T. b. gambiense disease is
active case-ﬁnding by mobile teams followed by treatment of
all infected patients [1,3]. Passive screening at health-care
facilities for the T. b. gambiense and T. b. rhodesiense infec-
tions is also crucial.
In addition, vector control by use of tsetse ﬂy traps or
screens helps to reduce ﬂy density [57]. In some areas, such
vector control activities are mainly implemented within the
Pan-African Tsetse and Trypanosomiasis Eradication Cam-
paign of the African Union. This goal is achieved through an
integrated strategy approach that combines insecticide spray-
ing, traps and the very-high-cost sterile insect technique,
although others argue for the use of simple technologies
such as traps in combination with insecticides [58,59]. In
regions where T. b. rhodesiense is endemic, the main chal-
lenge is to control the animal reservoir that represents the
risk of permanent transmission and unexpected epidemics.
Here, although a restricted application of insecticides to cat-
tle (especially belly and legs) represents a cost-effective
accessible method of vector control, the control of the
disease in wildlife and the vector in protected areas and
game reserves could be more complicated, because of
conservationist, ecological and environmental considerations
[1].
Following World Health Assembly resolutions 50.36 in
1967 and 56.7 in 2003, WHO committed itself to support
HAT-endemic countries in their efforts to remove the dis-
ease as a public health problem. Concurrently, HAT initia-
tives and public–private partnerships are currently
developing new methods to diagnose and treat patients and
to control transmission. The successful development and
implementation of these improved tools, and the sustainable
access of all populations at risk to surveillance and control
activities, are the remaining obstacles to reaching the objec-
tive of global HAT elimination.
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